Assessment of the effects of telmisalthan and olmethaltan on blood pressure, proteinuria, inflammation and oxidative stress in chronic kidney disease patients
Not Applicable
Recruiting
- Conditions
- Chronic kidney disease stage 3-5
- Registration Number
- JPRN-UMIN000002422
- Lead Sponsor
- Division of Nephrology Department of Medicine, Showa University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who has past history of adverse effect of taking another ARB 2) Pregnancy 3) Patients who has serious liver disease and coronary heart disease or nephrotic syndrome 4) Judged inappropriate for this study by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is the impact of termisartan and olmesartan on blood pressure, proteinuria at four and twelve months after administration of the ARB case compared with at baseline.
- Secondary Outcome Measures
Name Time Method The secondary outcome is the impact of termisartan and olmesartan on inflammatory and oxidative stress markers (hsCRP, IL-6, IL-10. TNF, pectsidine, PTX3, MPO, 8OHdG in urine)at four and twelve months after administration of the ARB case compared with at baseline